* 27% y-o-y organic sales growth in Q4'25e * No change to financial targets expected Q4'25 results d...
Scibase has now disclosed the final outcome of its rights issue, in addition to announcing the outco...
Redeye updates its estimates and valuation after VEF’s Q4 2025 report.
The Q4 report was a bit of a mixed bag, but there are some “extenuating circumstances”.
Alcadon continues to prioritise profitability and capital efficiency, underscored by its decision to...
* Strong orders should continue to convert into sales growth (17%) * Enedo stabilising as comps ease...
Redeye comments on Faron’s announcements of the phase I/II investigator-initiated trials BEXAR and B...
* Impairments of ~SEK 240m in Q4 * Preliminary Q4 EBIT of ~SEK -315m (vs.
* We forecast sales -27% y-o-y, driven by EEs -13% and FX -9% * Substantial market weakness, tough c...
We expect a strong positive share price reaction today of c15%, given the beat on sales, profitabili...
Ahead of CapMan's Q4 2025 results on 12 February, we make estimate revisions to reflect completed an...
* Regulatory evaluation successfully completed * Green light for the test panel to begin its work * ...
Train Alliance’s performance in 9M/25 was strong, with EBIT growth far outpacing revenue growth.
Ependion’s Q4 report was a bit weaker than we hoped for on sales and earnings.
We expect a Q4 with good earnings growth and a high number of starts.
* Softer Q4 numbers due to postponed orders... * ..
Prior to Taaleri's Q4 results on 11 February, we make several estimate changes, mainly reflecting pe...
We leave our DCF-derived fair equity value range of SEK 129-174 unchanged ahead Duni’s Q4 report.
Truecaller released preliminary Q4 2025 numbers this morning.
Today, Cantargia announced the recruitment of the first patient in a new study of nadunolimab in col...
